NHD Global
Growth Hormone & IGF · Long-acting GHRH analogue research
Scientific Product Dossier
CJC-1295 with DAC is a lab-made peptide based on growth hormone-releasing hormone. The DAC group lets it stick to albumin, a common blood protein, which makes it last far longer in the body than natural GHRH. In short studies of healthy adults, one injection raised average growth hormone for at least six days and IGF-1 for about nine to eleven days. Growth hormone was still released in bursts, but levels between bursts were higher. These studies tracked hormones only. They tell us nothing about long-term health or body composition. This is a research material, not a medicine, and not the same as CJC-1295 without DAC.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
Mean GH rose 2- to 10-fold for at least 6 days and mean IGF-1 rose 1.5- to 3-fold for 9–11 days; estimated half-life was 5.8–8.1 days.
Healthy adults, short ascending-dose studies, DAC form only.
Read the primary studyFDA identifies limited clinical data, immunogenicity/impurity concerns and serious reports including increased heart rate and systemic vasodilation.
FDA lists CJC-1295 generically in this public summary and does not resolve the marketed DAC/without-DAC form. It is not a finding about a specific catalog lot.
Read the primary studyTwo placebo-controlled studies lasted 28 and 49 days. After a single administration, mean GH increased approximately 2–10-fold for at least 6 days and IGF-I approximately 1.5–3-fold for 9–11 days.
These were pharmacokinetic and endocrine endpoints in adults aged 21–61. They do not establish long-term outcomes, and they must not be assigned to CJC-1295 without DAC.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Teichman SL, et al. Journal of Clinical Endocrinology & Metabolism. 2006. PMID 16352683.
View primary recordFrohman LA, et al. Journal of Clinical Endocrinology & Metabolism. 2006. PMID 17018654.
View primary recordThird-party publications selected for direct relevance.
Teichman SL, et al. J Clin Endocrinol Metab. 2006. PMID 16352683.
Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006. PMID 17018654.
Concise answers for researchers comparing identity, evidence and catalog variants.
Two early randomized studies gave single injections to healthy adults. Average growth hormone rose 2- to 10-fold for at least six days, and IGF-1 rose 1.5- to 3-fold for nine to eleven days. A separate small study found hormone bursts were preserved while levels between them increased. These track hormone levels only. They do not show long-term benefits.
Growth hormone is normally released in bursts, and that pattern matters. In a small study of healthy men, CJC-1295 raised hormone levels between bursts but the bursts themselves stayed similar in size and frequency. This suggests the peptide boosts the existing signal rather than replacing it. This finding is for the DAC form given to healthy men. It does not apply to CJC-1295 without DAC or to catalog material.
The drug-affinity-complex group supports albumin binding and prolonged exposure; it is the defining feature behind the published multi-day pharmacokinetics.
No. That estimate belongs to the albumin-binding form studied in the paper.
Family-level identifiers organize the catalog. Confirm the supplied form, identity and release criteria using the applicable product specification and ask which lot records are available.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
The classic CJC-1295 human paper evaluated a long-acting albumin-binding analog in healthy adults. Its sustained hormone profile is evidence for the DAC form studied—not…
Updated October 1, 2026
For CJC-1295 with DAC, the albumin-reactive group is not a branding detail. It changes persistence, analytical behavior and the relevance of the published human…
Updated October 13, 2026Source-traceable evidence
Structured readings of published studies, with the model, result and translation boundary stated explicitly.
Understand the hormone measurements before making claims about muscle or recovery.
Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: CD2 · 2 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
